Peptide-based PET radiotracer (Stanford University)

N/A

Report date: 2024/04/01 20:04:33
NME

Base Information

Drug NamePeptide-based PET radiotracer (Stanford University)
Drug Alias Name18F-FPPRGD2
ClassificationDiagnostic agent (In vivo)Small molecules > Synthetic peptide
Mechanisms of ActionIntegrin alpha-V/beta-3 antagonists
TargetsIntegrin alpha-V/beta-3
Therapy Area/IndicationsSolid tumoursAortic Aneurysm, AbdominalCarotid Artery Diseases +[26] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesStanford University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesStanford UniversityNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsSolid tumoursAortic Aneurysm, AbdominalCarotid Artery Diseases +[26] 

Other Information

ATC CodeN/A
Related LinksN/A